Morgan Stanley downgrades Novo Nordisk $NVO to Underweight citing heavy reliance on blockbuster drug Semaglutide!
KEY HIGHLIGHTS:
• Semaglutide expected to generate 75% of 2026 sales, creating a massive upcoming patent cliff risk
• Maintains elite core profitability with an
A global leader in crowdsourced U.S. investment research, powered by one of the largest and most vibrant investor communities.






